Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial

Kang, Jin Mo; Park, Ki Hyuk; Ahn, Sanghyun; Cho, Sungsin; Han, Ahram; Lee, Taeseung; Jung, In Mok; Kim, Jang Yong; Min, Sang Il

doi:10.1038/s41598-019-56887-w

Cited by 20 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We hypothesized that the duration of anticoagulation with rivaroxaban in this patient might have been insufficient. In the Kang et al study, 23 the rate of thrombus recurrence was lower in the rivaroxaban group than in the warfarin group. Being the first randomized controlled study 23 on thrombolysis in acute iliofemoral venous thrombosis to compare NOAC and VKA after CDT, the results complemented previous evidence and further supported the use of rivaroxaban after CDT.…”

Section: Discussionmentioning

confidence: 82%

“…In the Kang et al study, 23 the rate of thrombus recurrence was lower in the rivaroxaban group than in the warfarin group. Being the first randomized controlled study 23 on thrombolysis in acute iliofemoral venous thrombosis to compare NOAC and VKA after CDT, the results complemented previous evidence and further supported the use of rivaroxaban after CDT. One patient stopped taking the drug 4 months after discharge in this study.…”

Section: Discussionmentioning

confidence: 82%

See 1 more Smart Citation

Safety and Efficacy of Rivaroxaban for Inferior Vena Cava Thrombosis after Successful Catheter-Directed Thrombolysis

Nie

Yan

et al. 2021

Semin Thromb Hemost

View full text Add to dashboard Cite

Rivaroxaban use for inferior vena cava (IVC) thrombosis after successful catheter-directed thrombolysis (CDT) is rarely reported. This study aimed at investigating the safety and efficacy of rivaroxaban for IVC thrombosis after CDT. The clinical data on 38 consecutive patients with IVC thrombosis (68% male; mean age, 51.5 ± 16.5), who received rivaroxaban after CDT between July 2017 and January 2020, were retrospectively analyzed in this study. Safety and efficacy of rivaroxaban (bleedings and recurrent venous thromboembolism), cumulative prevalence of post-thrombotic syndrome (PTS), primary patency, clinically driven target lesion revascularization rate, and other adverse events including all-cause mortality and vascular events (systemic embolism, acute coronary syndrome, ischemic stroke, and transient ischemic attack) were retrospectively analyzed. Of the 38 patients who received rivaroxaban for IVC thrombosis after CDT, 27 (71%) had an anticoagulant duration of 6 months and 11 patients (29%) of more than 6 months. Four patients (10%) suffered recurrent thrombosis. No patient suffered major bleeding, while clinically relevant nonmajor bleeding occurred in two (5%) patients. The cumulative prevalence of PTS was 18% (7/38) during the 12 months follow-up period. Primary patency at 1, 3, 6, and 12 months was 97, 92, 90, and 90%, respectively. According to follow-up data, the clinically driven target lesion revascularization of this study was 10%. Cardiovascular events and mortality did not occur in any patient during the study period. Rivaroxaban for IVC thrombosis after successful CDT can be safe and effective.

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 82%

Safety and Efficacy of Rivaroxaban for Inferior Vena Cava Thrombosis after Successful Catheter-Directed Thrombolysis

Nie

Yan

et al. 2021

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…In current research overall drug compliance with antithrombotic drugs was reported in 296 (77.1%) DVT patients, whereas drug compliance with rivaroxaban was present in 103 (80.5%) patients followed by heparin drug compliance in 95 (74.2%) DVT patients and warfarin drug compliance in 98 (76.6%) patients. A similar study by Kang, JM, et al, [21] reported the overall drug compliance 93.8% with antithrombotic [24] and reported the higher drug compliance with rivaroxaban followed by heparin and warfarin [25][26][27].…”

Section: Discussionmentioning

confidence: 74%

Comparative Study of Compliance and Factors Affecting Compliance among Commonly Used Drugs in Deep Vein Thrombosis Patients

Ali

Mal

Ram

et al. 2021

JPRI

View full text Add to dashboard Cite

Objectives: The objective of current research was to identify the compliance of antithrombotic drug (heparin, warfarin and Rivaroxaban) and factors of non-compliance associated with heparin, warfarin and rivaroxaban. Methodology: A cross-sectional, observational study was conducted on patients suffering from Deep Vein Thrombosis (DVT) at government teaching hospital of Larkana. 348 DVT patients were selected by using online sample calculator software. Data was collected by using pre validated questionnaire after taking patient consent; finally the data was analyzed with statistical package of social sciences (SPSS) version 25. Results: The compliance with rivaroxaban was present in 103 (80.5%) patients followed by heparin drug compliance in 95 (74.2%) DVT patients and warfarin drug compliance in 98 (76.6%) DVT patients. Non-compliance factors with rivaroxaban were; cost in 4 (16.0%) patients, polypharmacy in 6 (24.0%) patients, side effects in 4 (16.0%) patients and prolong therapy in 11 (44.0%) patients. Non-compliance factors with heparin were; monitoring in 13 (39.4%) patients, diet restriction in 6 (18.2%) patients, injectable in 10 (30.3%) patients and ADR in 4 (12.1%) patients. Non-compliance factors with warfarin were; cost in 4 (13.3%) patients, polypharmacy in 8 (26.7%) patients, prolong therapy in 5 (16.7%) patients and ADR in 13 (43.3%) patients. Conclusion: This study concludes that rate of drug compliance was high in patients of DVT with rivaroxaban followed by warfarin and heparin, whereas long duration of therapy, polypharmacy, side effects of therapy, cost of therapy, continuous monitoring, injectables, diet restrictions and ADRs of therapy were the most commonly reported factors of non-compliance.

show abstract

“…In current research the drug compliance with rivaroxaban was present in (54.5%) patients followed by warfarin drug compliance in (42.5%) and drug compliance with heparin was (0.0%) DVT patients and patients. A similar study by Kang, J. M., et al, reported the overall drug compliance 93.8% with antithrombotic drugs, whereas drug compliance with rivaroxaban was 100.0% and warfarin drug compliance was 93.8%[18]. Similarly, different other studies such as; Lazo-Langner, A., et al, compared the heparin and rivaroxaban, Deitelzweig, S., et al, compared the warfarin and rivaroxaban [20], Al Khateep, Y. M., et al (2019) compared the warfarin and rivaroxaban [19] and Piati, P. K., et al (2019) Comparative Analysis of Compliance between Rivaroxaban with Heparin & Warfarin in the Management of Deep Vein Thrombosis Tertiary Care Hospital Larkana compared the heparin, warfarin and rivaroxaban…”

mentioning

confidence: 64%

Comparative Analysis of Compliance between Rivaroxaban with Heparin & Warfarin in the Management of Deep Vein Thrombosis Tertiary Care Hospital Larkana

Abbasi¹,

Ghoto²,

Arain³

et al. 2021

RADS J. Pharm. Pharm. Sci.

View full text Add to dashboard Cite

Objective: The objective behind this study is to evaluate the compliance and noncompliance, between standard therapy with latest oral anticoagulants (NOACs) with each other so as a head-to-head comparison will ever be available. Methodology: A descriptive observational study was conducted at SMBBMUH Larkana.The questionnaire (specially designed)was filled up to monitor the non-compliances associated with drugs used for the management of Deep Vein Thrombosis (DVT).The study was conducted on the 100 patients who were reported with DVT at tertiary care hospital SMBBMUH Larkana. A series of questions were asked from reported patients regarding symptoms and side effects. Finally the results were analyzed by using descriptive statistics. Results: Results show that out of 100 patients, male patients (79%) observed more than female(21%) and mostly patients perform indoor jobs (39%). Prevalence of DVT is high about 53% patients were suffering from DVT during 03 months. It was found that mostly patient non compliance observed with Warfarin (n=26) as compare to heparin (n=19) and Rivaroxaban (n=07). Conclusion: The study concluded that the more compliance achieved with Rivaroxaban as compared to warfarin and heparin. Mostly noncompliant factors are cost; prolong therapy, adverse drug reaction were common factors of non compliance in DVT patients.

show abstract

Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial

Cited by 20 publications

References 17 publications

Safety and Efficacy of Rivaroxaban for Inferior Vena Cava Thrombosis after Successful Catheter-Directed Thrombolysis

Safety and Efficacy of Rivaroxaban for Inferior Vena Cava Thrombosis after Successful Catheter-Directed Thrombolysis

Comparative Study of Compliance and Factors Affecting Compliance among Commonly Used Drugs in Deep Vein Thrombosis Patients

Comparative Analysis of Compliance between Rivaroxaban with Heparin & Warfarin in the Management of Deep Vein Thrombosis Tertiary Care Hospital Larkana

Contact Info

Product

Resources

About